Azenta will provide proteomics technology profiling on up to 20,000 individuals.

Azenta将为多达20000人提供蛋白质组学技术分析。

BURLINGTON, Mass., July 22, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced its participation in the FinnGen project, a large-scale research initiative at the forefront of personalized medicine in Finland. The FinnGen project is a pioneering endeavor that has collected and is currently analyzing genomic and health data from a cohort of 500,000 Finnish biobank participants..

马萨诸塞州伯灵顿，2024年7月22日/PRNewswire/--Azenta，Inc.（纳斯达克：AZTA）今天宣布参与FinnGen项目，这是芬兰个性化医学前沿的一项大规模研究计划。FinnGen项目是一项开创性的工作，它收集并正在分析来自500000名芬兰生物库参与者的基因组和健康数据。。

In collaboration with the University of Helsinki, the organization leading the FinnGen study, Azenta will provide comprehensive proteomics profiling on up to 20,000 individuals, underscoring Azenta's commitment to advancing healthcare innovation and personalized treatments. Azenta will use Olink's advanced proteomics technology, based on the proprietary Proximity Extension Assay, to provide high-quality protein-level measurements across all major biological pathways..

Azenta将与领导FinnGen研究的组织赫尔辛基大学合作，为多达20000人提供全面的蛋白质组学分析，强调Azenta致力于推进医疗创新和个性化治疗。Azenta将使用Olink的先进蛋白质组学技术，基于专有的邻近延伸分析，在所有主要生物途径中提供高质量的蛋白质水平测量。。

'FinnGen's adoption of proteomics marks a pivotal advancement in our quest to decode the complexities of human health and disease. By integrating the dynamic insights of proteomics with our extensive genomic data, we can gain a deeper understanding of disease mechanisms, identify new biomarkers for early detection, and uncover novel therapeutic targets.

芬根采用蛋白质组学标志着我们在探索人类健康和疾病的复杂性方面取得了关键进展。通过将蛋白质组学的动态见解与我们广泛的基因组数据相结合，我们可以更深入地了解疾病机制，确定用于早期检测的新生物标志物，并发现新的治疗靶点。

We are pleased to collaborate with Azenta Life Sciences, and trust that they will provide excellent service and deliver high-quality proteomic data with a fast turnaround time,' said Professor Aarno Palotie, FinnGen Scientific Director from the Institute for Molecular Medicine Finland (FIMM), University of Helsinki. 'Combined with excellent quality and reliable results, Azenta Life Sciences can help us construct a strong foundation for advancing the field of personalized medicine.'.

赫尔辛基大学芬兰分子医学研究所（FIMM）芬根科学主任阿诺·帕洛蒂（AarnoPalotie）教授说：“我们很高兴与Azenta Life Sciences合作，相信他们将提供优质的服务，并以快速的周转时间提供高质量的蛋白质组学数据。”。“结合卓越的质量和可靠的结果，Azenta Life Sciences可以帮助我们为推进个性化医疗领域奠定坚实的基础。”。

'As one of the collaborators in the FinnGen Project, Azenta looks forward to making meaningful contributions to personalized medicine and revolutionizing healthcare for generations to come,' said Ginger Zhou, PhD., Senior Vice President and General Manager, GENEWIZ Multiomics & Synthesis Solutions from Azenta Life Sciences.

“作为FinnGen项目的合作者之一，Azenta期待着为未来几代人的个性化医疗和医疗保健革命做出有意义的贡献，”Ginger Zhou博士说。，Azenta Life Sciences的GENEWIZ Multiomics&Synthesis Solutions高级副总裁兼总经理。

'Multiomics technologies from Azenta enable researchers to efficiently generate detailed proteomics data from study participants carrying medically and clinically significant genetic variants, opening up a world of possibilities for understanding disease mechanisms and developing targeted treatments.'.

“来自Azenta的多组学技术使研究人员能够有效地从携带医学和临床上重要遗传变异的研究参与者那里生成详细的蛋白质组学数据，为理解疾病机制和开发靶向治疗开辟了一个可能性的世界。”。

About FinnGen

FinnGen

FinnGen is a large public-private partnership aiming to collect and analyze genome and health data from 500,000 Finnish biobank participants. FinnGen aims on one hand to provide novel medically and therapeutically relevant insights but also construct a world-class resource that can be applied for future studies..

FinnGen是一个大型公私合作伙伴关系，旨在收集和分析来自500000名芬兰生物库参与者的基因组和健康数据。FinnGen一方面旨在提供新颖的医学和治疗相关见解，但也构建了一个世界级的资源，可用于未来的研究。。

FinnGen is one of the very first personalized medicine projects at this scale and the public-private collaborative nature of the project is exceptional compared to many ongoing studies. FinnGen brings together Finnish universities, hospitals and hospital districts, THL, Blood Service, biobanks, FINBB and international pharmaceutical companies and hundreds of thousands of Finns.

FinnGen是第一个如此规模的个性化医疗项目之一，与许多正在进行的研究相比，该项目的公私合作性质是特殊的。FinnGen汇集了芬兰大学、医院和医院区、THL、血液服务、生物银行、FINBB和国际制药公司以及数十万芬兰人。

Because collaboration is the key to achieving breakthroughs in disease prevention, diagnosis, and treatment, we welcome everyone on this journey into our shared heritage..

因为合作是在疾病预防、诊断和治疗方面取得突破的关键，我们欢迎在这段旅程中的每一个人成为我们共同的遗产。。

For more information, please visit https://www.finngen.fi/en.

有关更多信息，请访问https://www.finngen.fi/en.

About Azenta Life Sciences

关于Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research, and advanced cell therapies for the industry's top pharmaceutical, biotech, academic, and healthcare institutions globally.

Azenta，Inc.（纳斯达克：AZTA）是全球领先的生命科学解决方案提供商，能够更快地实现有影响力的突破和治疗。。

Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey and B Medical Systems..

我们的全球团队通过我们业界领先的品牌提供和支持这些产品和服务，包括GENEWIZ、FluidX、Ziath、4Titute、Limfinity、Freezer Pro、Barkey和B Medical Systems。。

Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

Azenta总部位于马萨诸塞州伯灵顿，业务遍及北美、欧洲和亚洲。。

'Safe Harbor Statement' under Section 21E of the Securities Exchange Act of 1934

1934年《证券交易法》第21E节规定的“安全港声明”

Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's financial and business results to differ materially from our expectations.

本新闻稿中的一些声明是根据1934年《证券交易法》第21E节做出的前瞻性声明。这些声明既不是承诺也不是保证，但涉及已知和未知的风险和不确定性，可能导致Azenta的财务和业务结果与我们的预期产生重大差异。

They are based on the facts known to management at the time they are made. Other forward-looking statements include but are not limited to statements about the prospects of the FinnGen Project and our ability to contribute to the advancement of personalized medicine. Factors that could cause results to differ from our expectations include the following: changes in technology and/or science that impact our ability to enable researchers to generate the proteomics data required to understand disease and develop targeted treatments and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, Current Reports on Form 8-K and our Quarterly Reports on Form 10-Q.

它们是基于制定时管理层已知的事实。其他前瞻性声明包括但不限于关于FinnGen项目前景的声明以及我们为推进个性化医疗做出贡献的能力。可能导致结果与我们的预期不同的因素包括：技术和/或科学的变化会影响我们的能力，使研究人员能够生成理解疾病和开发靶向治疗所需的蛋白质组学数据以及其他因素和其他风险，包括我们在向证券交易委员会提交的文件中描述的因素，包括但不限于我们在表格10-K上的年度报告，表格8-K上的当前报告以及表格10-Q上的季度报告。

As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based.

因此，我们无法保证我们的未来结果不会与预测结果有实质性差异。Azenta明确否认有义务或承诺公开发布任何此类声明的任何更新或修订，以反映我们的预期变化或任何此类声明所依据的事件、条件或情况的任何变化。

Azenta undertakes no obligation to update the information contained in this press release..

Azenta没有义务更新本新闻稿中包含的信息。。

INVESTOR CONTACTS:Yvonne PerronVice President, Financial Planning & Analysis, and Investor Relationsir@azenta.com

投资者联系人：Yvonne Perron财务规划与分析副总裁和投资者Relationsir@azenta.com

Sherry Dinsmoresherry.dinsmore@azenta.com

雪莉。Dinsmoresherry.dinsmore@azenta.com

Azenta's use of third-party trademarks and brands are for identification only and does not imply affiliation or endorsement. All trademarks used herein are the property of their respective owners.

Azenta使用第三方商标和品牌仅用于识别，并不意味着从属关系或认可。此处使用的所有商标均为其各自所有者的财产。

SOURCE Azenta

来源Azenta